Navigation Links
Elanco Launches Broad-Spectrum Canine Parasiticide
Date:1/17/2011

INDIANAPOLIS, Jan. 17, 2011 /PRNewswire/ -- Elanco Companion Animal Health has launched its second product in the new year with the launch of Trifexis™ (spinosad + milbemycin oxime), a broad-spectrum parasiticide that kills fleas and is indicated for the prevention and treatment of flea infestations, the prevention of heartworm disease and the treatment and control of adult hookworm, roundworm and whipworm infections in dogs and puppies 8 weeks and older, and 5 pounds of body weight or greater.

"Trifexis provides three types of parasite protection by combining two trusted active ingredients, spinosad and milbemycin oxime, into a convenient, monthly chewable tablet," said Steve Connell, DVM, director of technical, academic and consumer services for Companion Animal Health at Elanco. "It is a significant addition to the portfolio of parasiticide products available to veterinarians and pet owners. Trifexis is the fourth new product we have introduced in less than four years, delivering the innovation we promised when we launched Elanco Companion Animal Health."

Approved by the FDA, Trifexis starts killing fleas within 30 minutes and was 100% effective in four hours in a controlled laboratory study.(1) Trifexis also prevents heartworm disease caused by Dirofilaria immitis, and treats and controls adult hookworm (Ancylostoma caninum), roundworm (Toxocara canis & Toxascaris leonina) and whipworm (Trichuris vulpis) infections. The flavored chewable tablet can be offered like a treat, providing convenience for dog owners. It is available in five dosing sizes for dogs ranging from 5 to 120 lbs. Dogs greater than 120 lbs. may be treated by administering an appropriate combination of tablets.

The introduction of spinosad, one of the active ingredients in Trifexis, resulted in the receipt of a Presidential Green Chemistry Challenge Award(2) in 1999 from the U.S. Environmental Protection Agency. The award was presented to Dow AgroSciences LLC in the category of Designing Safer Chemicals for the introduction of spinosad as an insect control product for use on crops. This award demonstrates that spinosad as a technology for insect control has a favorable environmental profile. This award is not relevant to the safety and efficacy of Trifexis, nor does it confer any environmental benefit to Trifexis.

Trifexis is a prescription medication, available only through licensed veterinarians. To reinforce dispensing within the context of a valid veterinarian/client/patient relationship, all boxes and cartons of Trifexis contain a unique product tracking code.

Trifexis is the third product in Elanco's parasiticide portfolio. Comfortis® (spinosad), the first FDA-approved, chewable beef-flavored tablet that kills and prevents fleas for a full month, was launched in 2007. Comfortis quickly became a valuable tool in the fight against fleas, particularly in the flea-endemic Gulf Coast region of the U.S., where veterinarians have made Comfortis their No. 1 choice for dogs.(3) Assurity™, a topical flea treatment for cats, was registered with the EPA and launched earlier in January.

For more information about Trifexis, pet owners should ask their veterinarian or visit trifexis.com.About ElancoElanco is a global innovation-driven company that develops and markets products to improve animal health and food animal production in more than 75 countries. Elanco employs more than 2,300 people worldwide, with offices in more than 40 countries, and is a division of Eli Lilly and Company, a leading global pharmaceutical corporation. Additional information about Elanco is available at www.elanco.com.

Important safety information about TrifexisSerious adverse reactions have been reported following concomitant extra-label use of ivermectin with spinosad alone, one of the components of Trifexis chewable tablets. Treatment with fewer than three monthly doses after the last exposure to mosquitoes may not provide complete heartworm prevention. Prior to administration of Trifexis, dogs should be tested for existing heartworm infection. Use with caution in breeding females. The safe use of Trifexis in breeding males has not been evaluated. Use with caution in dogs with pre-existing epilepsy. Puppies less than 14 weeks of age may experience a higher rate of vomiting. If vomiting occurs within an hour of administration, redose with another full dose. The most common adverse reactions recorded during clinical trials were vomiting, pruritus, lethargy and diarrhea. For product label, including complete safety information, see attached.

Important safety information about ComfortisThe most common adverse reaction reported is vomiting. Other adverse reactions reported in decreasing order of frequency are: depression/lethargy, decreased appetite, incoordination, diarrhea, itching, trembling, excessive salivation and seizures. Following concomitant extra-label use of ivermectin with Comfortis, some dogs have experienced the following clinical signs: trembling/twitching, salivation/drooling, seizures, incoordination, excessive dilation of pupils, blindness and disorientation. Post-approval experience continues to support the safety of Comfortis when used concurrently with heartworm preventatives according to label directions. For product label, including complete safety information, see attached label.

About AssurityAlways read, understand and follow label and use directions.

(1) For full study details, see Comfortis FOI: NADA 141-277 at www.fda.gov.

(2) The Presidential Green Chemistry Challenge Award; www.epa.gov

(3) Ipsos-Forward/Elanco Market Research, August 2010

©2011 Elanco TFX00111 010411CONTACT:

Joan Todd (Elanco) — 317-277-7464Sharon Polk (McCormick Co.) — 816-584-8444
'/>"/>

SOURCE Elanco Companion Animal Health
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. American Medical Systems Launches STEP Patient Education Program in Europe
2. DST HealthCare Launches Medical Drug Management Service™
3. Verathon® Maker of BladderScan® and GlideScope® Medical Instruments Launches New Website
4. Siemens Launches PEP, a Personalized Education Plan for Clinical Laboratory and Healthcare Professionals
5. De Novo Software Launches New Version of FCS Express for Flow and Image Cytometry
6. CoreLab Partners Launches Advanced Imaging Application
7. FDA Launches Website To Help Regulated Industries Save Time, Resources
8. State Launches Immunize for Good Marketing Campaign to Remind Parents Immunizations are Safe and the Best Way to Prevent Childhood Illness
9. CVS/pharmacy Launches ExtraCare Beauty Club
10. Cell Biosciences Launches New Platform for Multiplex Western Blot Detection
11. CutisPharma Launches New Prescription Mouthwash Kits Expanding Product Line
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... , June 24, 2016 Research and ... Market for Companion Diagnostic Tests" report to their offering. ... for Companion Diagnostics The World Market for ... personalized medicine diagnostics. Market analysis in the report includes the ... Market (In Vitro Diagnostic Kits) by Region (N. America, EU, ...
(Date:6/24/2016)... , Belgium , June 24, ... VNRX), today announced the appointment of Dr. ... Directors as a Non-Executive Director, effective June 23, ... Audit, Compensation and Nominations and Governance Committees.  As ... Futcher will provide independent expertise and strategic counsel ...
(Date:6/23/2016)... June 23, 2016 Research and Markets ... Market - Forecast to 2022" report to their offering. ... method for the patients with kidney failure, it replaces the ... from the patient,s blood and thus the treatment helps to ... chloride in balance. Increasing number of ESRD ...
Breaking Medicine Technology:
(Date:6/26/2016)... (PRWEB) , ... June 27, 2016 , ... Quality metrics ... yet in many ways they remain in the eye of the beholder, according to ... a publication of The American Journal of Managed Care. For the full issue, ...
(Date:6/26/2016)... ... ... legally blind and certified personal trainer is helping to develop a weight loss fitness plan ... fix the two major problems leading the fitness industry today:, , ... They don’t eliminate all the reasons people quit their exercise program ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... The temporary closing of Bruton Memorial Library ... City Observer , brings up a new, often overlooked aspect of head lice: the parasite’s ... for fumigation is not a common occurrence, but a necessary one in the event that ...
(Date:6/25/2016)... ... June 25, 2016 , ... ... non-athletes recover from injury. Recently, he has implemented orthobiologic procedures as a method ... —Johnson is one of the first doctors to perform the treatment. Orthobiologics are ...
(Date:6/24/2016)... ... June 24, 2016 , ... Those who have experienced traumatic events may suffer ... unhealthy avenues, such as drug or alcohol abuse, as a coping mechanism. To avoid ... healthy coping following a traumatic event. , Trauma sufferers tend to feel a range ...
Breaking Medicine News(10 mins):